Characterization of MDMA analogue 1,3-benzodioxolylbutanamine (BDB) and its structural analogues
Nina Kastner, Julian Maier, Marion Holy, Fatemeh Kooti, Bruce E Blough, Joseph Wilson, Kevin Murnane, Harald H. Sitte · FENS Forum 2024
3,4-Methylenedioxymethamphetamine (MDMA) is researched in clinical trials as possible complementary treatment to psychotherapy in depression and posttraumatic stress disorder. It received break-through status after clinical evidence showed its potential, although questions regarding its abuse potential and cytotoxicity persist. There has been interest in exploring similar alternative substances that may retain therapeutic benefits while reducing adverse events. In this study, we characterized MDMA analogue 1,3-benzodioxolylbutanamine (BDB) and its structural analogue N-methyl-1,3-benzodioxolyl
ePoster · Neuroscience